Lisa Bright

Lisa Bright

Commercial Advisor

Lisa is a Commercial Advisor to Syncona Investment Management Ltd.

Lisa is a senior commercial leader and board member with over 30 years’ experience in biopharmaceuticals, serving in executive and general management roles where she has developed expertise in launching innovative specialty medicines. Most recently Lisa served as President International and Chief Commercial and Corporate Affairs Officer for Intercept Pharmaceuticals Inc. where she established the global commercial footprint and launch for an orphan drug. Previously, Lisa held a variety of senior roles at Gilead Sciences as VP Head International Government Affairs, VP Head HCV International Launch Planning, VP Head Northern Europe and VP and General Manager UK. Prior to that, at GlaxoSmithKline she was VP Commercial Strategy International, VP General Manager New Zealand, and VP Head Primary Care Sales.

Lisa currently serves on the Boards of several public and private companies including Ascendis Pharma AS, Dechra Pharmaceuticals Plc, Immedica Pharma AB and Resolution Therapeutics Ltd and also is on the Strategic Advisory Board for DRI Capital. She holds a B.Sc.Hons in Pharmacology from University College London.

Syncona portfolio companies

  • Resolution Therapeutics (Board member)
Martin Murphy

Martin Murphy

Chief Executive Officer
Chris Hollowood

Chris Hollowood

Chief Investment Officer
Markus John

Markus John

Chief Medical Officer and Head of R&D
Elisa Petris

Elisa Petris

Partner
Alice Renard

Alice Renard

Partner
Ben Woolven

Ben Woolven

Business Strategy and Operations Partner
Raghd Rostom

Raghd Rostom

Associate Partner